Injection site reactions are a common side effect of GLP-1s like semaglutide or tirzepatide, affecting around 1% to 8% of people taking the medications
An important example is insulin resistance: reduced glucose uptake in cancer patients compared with healthy controls during an euglycemic hyperinsulinemic glucose clamp has commonly been observed not only during 7, 8 but also before weight loss or malnutrition
Glycemic Improvement and Diabetes Prevention: Semaglutide's glucose-dependent insulin secretion stimulation and glucagon suppression improve postprandial glycemic control regardless of diabetes status
(1998) study in rats, ipamorelin produced GH release comparable to GHRP-6 but with substantially less cortisol and prolactin co-release, which is the pharmacological basis for its "cleaner" secretagogue reputation
Glucagon-like peptide 1 (GLP-1) infusion in healthy men during prolonged fasting does not cause reactive hypoglycemia
Immune System Support Research indicates that glutathione peptides may bolster the immune system
